AU2002213925A1 - Use of glp-1 and flp-2 peptides for treatment of bone disorders - Google Patents

Use of glp-1 and flp-2 peptides for treatment of bone disorders

Info

Publication number
AU2002213925A1
AU2002213925A1 AU2002213925A AU1392502A AU2002213925A1 AU 2002213925 A1 AU2002213925 A1 AU 2002213925A1 AU 2002213925 A AU2002213925 A AU 2002213925A AU 1392502 A AU1392502 A AU 1392502A AU 2002213925 A1 AU2002213925 A1 AU 2002213925A1
Authority
AU
Australia
Prior art keywords
treatment
flp
glp
peptides
bone disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002213925A
Other languages
English (en)
Inventor
Dennis Bang Henriksen
Jens Juul Holst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunodiagnostic Systems Nordic AS
Original Assignee
Osteometer Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0022844A external-priority patent/GB0022844D0/en
Priority claimed from GB0029920A external-priority patent/GB0029920D0/en
Application filed by Osteometer Biotech AS filed Critical Osteometer Biotech AS
Publication of AU2002213925A1 publication Critical patent/AU2002213925A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002213925A 2000-09-18 2001-09-17 Use of glp-1 and flp-2 peptides for treatment of bone disorders Abandoned AU2002213925A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0022844.5 2000-09-18
GB0022844A GB0022844D0 (en) 2000-09-18 2000-09-18 Use of GLP-1 and GLP-2 peptides
GB0029920A GB0029920D0 (en) 2000-12-07 2000-12-07 Use of glp-1 and glp-2 peptides
GB0029920.6 2000-12-07
PCT/EP2001/010714 WO2002022151A2 (en) 2000-09-18 2001-09-17 Use of glp-1 and flp-2 peptides for treatment of bone disorders

Publications (1)

Publication Number Publication Date
AU2002213925A1 true AU2002213925A1 (en) 2002-03-26

Family

ID=26245018

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002213925A Abandoned AU2002213925A1 (en) 2000-09-18 2001-09-17 Use of glp-1 and flp-2 peptides for treatment of bone disorders
AU2001287892A Abandoned AU2001287892A1 (en) 2000-09-18 2001-09-18 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001287892A Abandoned AU2001287892A1 (en) 2000-09-18 2001-09-18 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders

Country Status (11)

Country Link
US (2) US6770620B2 (ja)
EP (3) EP1970072A1 (ja)
JP (2) JP5161412B2 (ja)
AT (2) ATE396738T1 (ja)
AU (2) AU2002213925A1 (ja)
CY (2) CY1108263T1 (ja)
DE (2) DE60134251D1 (ja)
DK (2) DK1326630T3 (ja)
ES (2) ES2310192T3 (ja)
PT (2) PT1326630E (ja)
WO (2) WO2002022151A2 (ja)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186683B2 (en) * 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US20070135345A1 (en) * 2000-09-18 2007-06-14 Henriksen Dennis B Use of GLP-2 for the treatment or prevention, of bone-related disorders
EP1970072A1 (en) * 2000-09-18 2008-09-17 Sanos Bioscience A/S Use of GLP-2 peptides for the treatment of hyperparathyroidism
RO120121B1 (ro) * 2000-12-18 2005-09-30 Elena Ionaşcu Soluţie injectabilă, cu efect antiinflamator, procedeu de obţinere şi metodă de tratament a bolilor autoimune
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
DE10135315A1 (de) * 2001-07-19 2003-01-30 Bayer Ag Stents
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
KR101072885B1 (ko) * 2002-05-17 2011-10-17 듀크 유니버시티 비만치료방법
WO2004084859A2 (en) * 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
WO2004085471A2 (en) * 2003-03-24 2004-10-07 Novo Nordisk A/S Glp-2 derivatives
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
PT2316456T (pt) * 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
CN1822851B (zh) 2003-05-15 2011-04-13 塔夫茨大学信托人 肽和多肽药物的稳定类似物
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
CA2553207A1 (en) * 2004-01-13 2005-08-04 Kishore M. Gadde Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
CA2565154A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
EP2295452A1 (en) 2005-05-04 2011-03-16 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
WO2006135660A2 (en) * 2005-06-10 2006-12-21 University Of Chicago Therapies involving lymphotoxin beta receptor
JP5180092B2 (ja) * 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
AU2007249736A1 (en) * 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CA2669806C (en) 2006-11-08 2018-10-02 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues
AU2007319472B2 (en) * 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
CN101588795A (zh) 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂
WO2008116004A2 (en) 2007-03-19 2008-09-25 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
CA2699008A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
EP2341942A1 (en) 2008-09-19 2011-07-13 Nektar Therapeutics Polymer conjugates of therapeutic peptides
WO2010042145A1 (en) * 2008-09-19 2010-04-15 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
DK2349324T3 (en) 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
BR112012006437A2 (pt) 2009-09-23 2016-04-19 Biokier Inc composições e métodos para tratamento do diabetes e outros distúrbios
EP2311486A1 (en) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 for use in intestine and muscle recovery
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP2014518875A (ja) * 2011-05-24 2014-08-07 ポリヴァロール ソシエテ アン コマンディト 特定のキトサン系ナノ複合体を用いてｓｉＲＮＡを効果的かつ安全に送達するための組成物及び方法
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CA2872315A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
HUE049859T2 (hu) 2012-06-06 2020-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatnak kitett páciensekben túlsúly és elhízás kezelésére szolgáló eljárásban történõ alkalmazásra
EP3517122A1 (en) 2013-04-03 2019-07-31 Sanofi Treatment of diabetes mellitus by long-acting formulations of insulins
WO2015016682A1 (ko) 2013-08-01 2015-02-05 경희대학교 산학협력단 당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법
KR101688639B1 (ko) 2013-08-01 2016-12-21 경희대학교 산학협력단 당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
CA2990230A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
WO2018009778A1 (en) * 2016-07-07 2018-01-11 Baylor College Of Medicine Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
EP3526242A1 (en) 2016-10-12 2019-08-21 University of Copenhagen Peptide dual agonists of gipr and glp2r
BR112019010624A2 (pt) 2016-12-09 2019-10-22 Zealand Pharma As agonistas duplos de glp-1/glp-2 acilados e composição
WO2019072963A1 (en) 2017-10-12 2019-04-18 University Of Copenhagen POLYTHERAPY FOR THE TREATMENT OF BONE DISEASES
EP3699187A1 (en) 2019-02-21 2020-08-26 Universite D'angers Peptide targeting gip and glp-2 receptors for treating bone disorders
US20210187077A1 (en) * 2019-12-23 2021-06-24 Idaho State University GLP-1 Agonist Conjugates for Sustained Glycemic Control
JP2023508175A (ja) * 2019-12-24 2023-03-01 ハンミ ファーマシューティカル カンパニー リミテッド Ｇｌｐ－２又はその結合体を含む、代謝性骨疾患の予防又は治療用薬学的組成物
US20230355720A1 (en) * 2020-09-25 2023-11-09 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating bone diseases, comprising triple agonist or conjugate thereof having activity with respect to all of glucagon, glp-1 and glp receptors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1498425A1 (en) 1986-05-05 2005-01-19 The General Hospital Corporation Use of glucagone-like-peptide 1 (GLP-1) derivatives for the preparation of pharmaceutical compositions
DE68929217T2 (de) 1989-03-20 2000-11-30 The General Hospital Corp., Boston Insulinotropes hormon
WO1991011457A1 (en) 1990-01-24 1991-08-08 Buckley Douglas I Glp-1 analogs useful for diabetes treatment
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5512459A (en) 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP1231218B1 (en) * 1996-03-01 2008-05-14 Novo Nordisk A/S An appetite-suppressing peptide, its compositions and use
US5912229A (en) 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
EP0906338B1 (en) 1996-04-12 2002-11-06 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
WO1998001535A1 (en) 1996-07-05 1998-01-15 Novo Nordisk A/S Method for the production of polypeptides
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
JP2000517308A (ja) 1996-08-30 2000-12-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―２誘導体
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DK1012186T3 (da) 1996-12-06 2002-11-04 Amgen Inc Keratinocyt-vækstfaktorer og anvendelser deraf
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2274989C (en) 1996-12-13 2012-01-31 Allelix Biopharmaceuticals Inc. Cloned glucagon-like peptide-2 receptors
US6077949A (en) 1996-12-13 2000-06-20 Allelix Biopharmaceuticals, Inc. Cloned glucagon-like peptide 2 receptors
US6051557A (en) 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
WO1998052600A1 (en) * 1997-05-16 1998-11-26 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
WO1999006059A2 (en) 1997-07-30 1999-02-11 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
WO1999014239A1 (de) 1997-09-12 1999-03-25 Wolf Georg Forssmann Zusammensetzung zur therapie von diabetes mellitus und fettsucht
JP2003525570A (ja) 1998-01-23 2003-09-02 ノボ ノルディスク アクティーゼルスカブ 酵母において所望のポリペプチドを産生する方法
CA2319195A1 (en) 1998-02-02 1999-08-05 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
AU2712899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
WO1999046283A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU7421598A (en) 1998-05-11 1999-11-29 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
BR9913153A (pt) 1998-08-21 2001-05-15 Point Therapeutics Inc Normalização da atividade do substrato
US6193997B1 (en) 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
WO2000020592A1 (en) 1998-10-07 2000-04-13 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
DK1137666T5 (da) 1998-12-07 2009-10-05 Univ Tulane GLP-1-analoger
CZ295768B6 (cs) 1998-12-07 2005-10-12 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající beta-alanin na pozici 35, jejich použití a farmaceutické prostředky je obsahující
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
GB9905416D0 (en) 1999-03-09 1999-05-05 Allelix Biopharma Small molecules having GLP-2 like activity
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AU2020501A (en) 1999-12-08 2001-06-18 1149336 Ontario Inc. Chemotherapy treatment
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
EP1695983B1 (en) * 2000-06-16 2009-03-04 Eli Lilly & Company Glucagon-like peptide-1 analogs
EP1305338A2 (en) * 2000-08-02 2003-05-02 Theratechnologies Inc. Modified peptides with increased potency
EP1970072A1 (en) * 2000-09-18 2008-09-17 Sanos Bioscience A/S Use of GLP-2 peptides for the treatment of hyperparathyroidism
WO2002066062A2 (en) * 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity

Also Published As

Publication number Publication date
ES2345874T3 (es) 2010-10-05
WO2002024214A2 (en) 2002-03-28
EP1414486B1 (en) 2010-05-05
AU2001287892A1 (en) 2002-04-02
PT1326630E (pt) 2008-09-02
US20020037836A1 (en) 2002-03-28
WO2002022151A3 (en) 2003-03-13
US6943151B2 (en) 2005-09-13
EP1414486A2 (en) 2004-05-06
JP5161412B2 (ja) 2013-03-13
EP1326630B1 (en) 2008-05-28
JP2004524268A (ja) 2004-08-12
US20040082507A1 (en) 2004-04-29
WO2002022151A2 (en) 2002-03-21
ES2310192T3 (es) 2009-01-01
EP1326630A2 (en) 2003-07-16
ATE466592T1 (de) 2010-05-15
DE60134251D1 (de) 2008-07-10
JP5189723B2 (ja) 2013-04-24
WO2002024214A3 (en) 2004-02-19
CY1108263T1 (el) 2014-02-12
ATE396738T1 (de) 2008-06-15
EP1970072A1 (en) 2008-09-17
US6770620B2 (en) 2004-08-03
DK1326630T3 (da) 2008-09-15
CY1110721T1 (el) 2015-06-10
DE60142084D1 (de) 2010-06-17
DK1414486T3 (da) 2010-08-30
PT1414486E (pt) 2010-07-21
JP2004508410A (ja) 2004-03-18

Similar Documents

Publication Publication Date Title
AU2002213925A1 (en) Use of glp-1 and flp-2 peptides for treatment of bone disorders
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
MXPA03003870A (es) Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
WO2003018516A3 (en) Glucagon-like peptide-1 analogs
HK1046845A1 (en) Vibrator for lower limbs, and chair type vibrator using the vibrator.
AU2002220651A1 (en) Steerable loop structure
PL362690A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
WO2004021968A3 (en) Solution for ungual application
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
EP1210915A3 (en) Laser treatment apparatus
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
AU2001252605A1 (en) Laser treatment apparatus
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
AU6028001A (en) Endoprosthesis part for use in joint replacement, use of the same and productionmethod therefor
MXPA03006249A (es) Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procesos de preparacion y su uso terapeutico.
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
WO1999053064A3 (en) Methods of delivering glp-1
PL356366A1 (en) Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
WO2002066513A3 (de) Humane zirkulierende lekti fragmente hf7072, hf7638 und hf14448 sowie ihre verwendung
WO2001089550A3 (en) Use of ciliary neurotrophic factor
WO2001078765A3 (de) Prophylaxe und therapie von diabetes mellitus 1 mit hilfe proteolytischer enzyme
HK1049477A1 (en) Apparatus for beauty treatment.
EP1331269A4 (en) NEW PROTEIN, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF